Page 124 - Read Online

Page 10 of 10 Simsek et al. Hepatoma Res 2020;6:11 I http://dx.doi.org/10.20517/2394-5079.2019.51

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
This retrospective study was approved by Johns Hopkins IRB NA_00028034.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. Liver transplantation for the treatment of small hepatocellular
carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
2. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor
size limits does not adversely impact survival. Hepatology 2001;33:1394-403.
3. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, et al. Predicting survival after liver transplantation in patients with
hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.
4. Andreou A, Gul S, Pascher A, Schoning W, Al-Abadi H, et al. Patient and tumour biology predict survival beyond the Milan criteria in
liver transplantation for hepatocellular carcinoma. HPB (Oxford) 2015;17:168-75.
5. Marshall AE, Rushbrook SM, Vowler SL, Palmer CR, Davies RJ, et al. Tumor recurrence following liver transplantation for
hepatocellular carcinoma: role of tumor proliferation status. Liver Transpl 2010;16:279-88.
6. Llovet JM, Paradis V, Kudo M, Zucman-Rossi J. Tissue biomarkers as predictors of outcome and selection of transplant candidates
with hepatocellular carcinoma. Liver Transpl 2011;17 Suppl 2:S67-71.
7. Fernandez-Sevilla E, Allard MA, Selten J, Golse N, Vibert E, et al. Recurrence of hepatocellular carcinoma after liver transplantation:
is there a place for resection? Liver Transpl 2017;23:440-7.
8. de’Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: a
systematic review. World J Gastroenterol 2015;21:11185-98.
9. Chok K. Management of recurrent hepatocellular carcinoma after liver transplant. World J Hepatol 2015;7:1142-8.
10. Kornberg A, Kupper B, Tannapfel A, Katenkamp K, Thrum K, et al. Long-term survival after recurrent hepatocellular carcinoma in
liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol 2010;36:275-80.
11. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns
and prognosis. Liver Transpl 2004;10:534-40.
12. Gurakar A, Ma M, Garonzik-Wang J, Kim A, Anders RA, et al. Clinicopathological distinction of low-AFP-secreting vs. high-AFP-
secreting hepatocellular carcinomas. Ann Hepatol 2018;17:1052-66.
13. Guerrero-Misas M, Rodriguez-Peralvarez M, De la Mata M. Strategies to improve outcome of patients with hepatocellular carcinoma
receiving a liver transplantation. World J Hepatol 2015;7:649-61.
14. Chok KS, Chan SC, Cheung TT, Chan AC, Fan ST, et al. Late recurrence of hepatocellular carcinoma after liver transplantation. World
J Surg 2011;35:2058-62.
15. Zhang JA, Kwee SA, Wong LL. Late recurrence of hepatocellular carcinoma after liver transplantation. Hepatoma Res 2017;3:58-66.
16. Rubin J, Ayoub N, Kaldas F, Saab S. Management of recurrent hepatocellular carcinoma in liver transplant recipients: a systematic
review. Exp Clin Transplant 2012;10:531-43.
17. Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol 2014;20:10223-37.
18. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med
2008;359:378-90.
19. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with
advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
20. Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol
2018;15:599-616.
21. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
22. Munker S, De Toni EN. Use of checkpoint inhibitors in liver transplant recipients. United European Gastroenterol J 2018;6:970-3.
23. Matter MS, Decaens T, Andersen JB, Thorgeirsson SS. Targeting the mTOR pathway in hepatocellular carcinoma: current state and
future trends. J Hepatol 2014;60:855-65.
24. Liang W, Wang D, Ling X, Kao AA, Kong Y, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular
carcinoma: a meta-analysis. Liver Transpl 2012;18:62-9.
25. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-fetoprotein decrease from > 1,000 to < 500 ng/mL in patients with
hepatocellular carcinoma leads to improved posttransplant outcomes. Hepatology 2019;69:1193-205.